Financials in USD. Standardized financial statements.
A compact view of how Knight Therapeutics Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $449.72M | $371.30M | $328.20M | $293.56M | $243.48M | $199.52M | $47.46M | $12.50M | $8.63M | $5.94M |
| Revenue Growth? | +21.1% | +13.1% | +11.8% | +20.6% | +22.0% | +320.4% | +279.7% | +44.8% | +45.4% | 0.0% |
| Cost of Revenue? | $299.10M | $196.90M | $175.55M | $155.50M | $128.07M | $117.83M | $20.54M | $2.31M | $1.58M | $1.55M |
| Gross Profit? | $150.62M | $174.41M | $152.65M | $138.06M | $115.41M | $81.69M | $26.92M | $10.20M | $7.05M | $4.39M |
| Gross Margin? | +33.5% | +47.0% | +46.5% | +47.0% | +47.4% | +40.9% | +56.7% | +81.6% | +81.6% | +73.9% |
| Operating Expenses? | $152.82M | $167.01M | $155.54M | $155.12M | $128.24M | $111.69M | $39.58M | $15.98M | $15.96M | $12.23M |
| Operating Income? | -$2.20M | $7.40M | -$2.89M | -$2.40M | -$5.32M | -$3.44M | $13.99M | -$17.56M | -$10.33M | -$8.04M |
| EBITDA? | $54.32M | $64.38M | $40.90M | $25.26M | $42.59M | $28.64M | $27.42M | -$3.85M | -$7.28M | -$7.40M |
| Income Before Tax | -$6.70M | $2.05M | -$21.99M | -$43.96M | $6.69M | $32.09M | $22.78M | $29.46M | $21.20M | $23.47M |
| Income Tax Expense | -$1.33M | -$2.28M | -$5.15M | -$14.07M | -$8.98M | $325,000 | $4.75M | $5.38M | $3.96M | $4.91M |
| Net Income? | -$5.37M | $4.33M | -$16.84M | -$29.89M | $15.68M | $31.76M | $14.52M | $24.08M | $17.24M | $18.56M |
| EPS? | $-0.05 | $0.04 | $-0.16 | $-0.26 | $0.13 | $0.24 | $0.10 | $0.17 | $0.12 | $0.15 |
| Diluted EPS? | $-0.05 | $0.04 | $-0.16 | $-0.26 | $0.13 | $0.24 | $0.10 | $0.17 | $0.12 | $0.15 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality